Ticagrelor Market

Market Overview

The global Ticagrelor Market was valued at approximately USD 1.89 billion in 2024 and is projected to reach USD 3.3 billion by 2033, growing at a CAGR of 7.66% during the forecast period (2025–2033).

Ticagrelor is a medicine taken by mouth that helps prevent serious heart problems like heart attacks and strokes. It is mainly used for people who have had a heart attack or have a condition called acute coronary syndrome (ACS), which means the heart isn’t getting enough blood. Ticagrelor belongs to a group of drugs that stop blood cells called platelets from sticking together and forming harmful clots. Unlike some older medicines, it works quickly and reliably because it doesn’t need to be changed by the body before it starts working. This makes it a popular choice for doctors. The demand for ticagrelor is growing as more people around the world suffer from heart diseases and as new and better treatments are developed. It is sold by the company AstraZeneca under the name Brilintaor or Brilique in some countries.

Some of the main features of ticagrelor are that it is absorbed into the body quickly, its effects can be reversed, and it doesn’t stay in the body too long, which helps doctors manage treatment more easily. As patents expire, more companies may start making their own versions of ticagrelor, especially in developing countries, which could make it more widely available and affordable.

Market Dynamics

Market Drivers

Rising global burden of cardiovascular diseases (CVDs)

Heart disease remaining the leading cause of death worldwide, there is an increasing need for effective antiplatelet therapies to prevent life-threatening events such as heart attacks and strokes. Aging populations, sedentary lifestyles, unhealthy diets, and growing rates of diabetes and hypertension are all contributing to the surge in CVD cases.

Ticagrelor, with its proven efficacy in reducing cardiovascular risks, is seeing greater demand as healthcare providers look for reliable and fast-acting treatments to manage these conditions.

Advancement of healthcare infrastructure and increasing awareness about heart health

The advancement of healthcare infrastructure and increasing awareness about heart health, especially in emerging markets. As countries in Asia, Latin America, and the Middle East continue to invest in better healthcare systems and expand access to treatment, more patients are being diagnosed and treated for heart-related conditions.

Alongside this, public health campaigns and educational efforts have led to earlier diagnosis and better management of risk factors. These developments are creating a favorable environment for the wider adoption of ticagrelor, especially as generic versions become available and lower the cost, making the drug more accessible to a broader patient base.

Market Restraints

High cost compared to other antiplatelet drugs

A major restraint in the ticagrelor market is its high cost compared to other antiplatelet drugs, particularly generic alternatives like clopidogrel. While ticagrelor offers superior efficacy and a faster onset of action, its premium pricing can limit accessibility, especially in low- and middle-income countries where healthcare budgets are constrained and out-of-pocket costs are high. This can lead physicians and healthcare providers to favor more affordable options, even if they are slightly less effective.

Additionally, in markets where insurance coverage is limited or reimbursement policies are restrictive, patients may struggle to afford long-term use of ticagrelor, which is typically prescribed for extended periods after a cardiac event. The high cost also poses challenges for widespread adoption in public healthcare systems, making pricing a critical barrier to market expansion, particularly in resource-limited settings.

Segmental Analysis

The Ticagrelor Market is segmented by product type ,Dosage form ,Indication ,Distribution Channels and End User. Each factor plays a crucial role in expanding patient access, improving treatment outcomes, and meeting regulatory standards in cardiovascular care.

By Product Type

Branded Drugs (e.g., Brilinta by AstraZeneca) currently dominate the market due to strong physician trust, proven clinical efficacy, and brand recognition. These drugs are often preferred in high-income countries and well-equipped hospital settings.

However, their high cost limits access in price-sensitive markets. Generic Drugs are rapidly gaining traction, particularly in developing countries and regions with cost-conscious healthcare systems. With patent expiration in several regions, generics are becoming more widely available, increasing affordability and boosting overall market penetration.

By Dosage Form

90 mg Tablets are commonly prescribed during the initial phase of treatment for acute coronary syndrome or myocardial infarction and represent a major share of the market due to their critical role in early intervention.  60 mg Tablets are typically used in the long-term maintenance phase post-cardiovascular events, especially when continued dual antiplatelet therapy (DAPT) is needed.

This dosage form supports sustained demand for chronic use. Other Formulations, such as modified-release or combination therapies, are limited but may see future development as companies explore new delivery formats to improve compliance and reduce side effects.

By Indication

Acute Coronary Syndrome (ACS) is the leading indication for ticagrelor use, driven by rising incidence rates and guidelines recommending ticagrelor over older drugs like clopidogrel for high-risk patients. Myocardial Infarction represents a significant portion of the market, as ticagrelor is widely used in both prevention and post-event recovery due to its superior efficacy in reducing recurrent cardiac events.

Stroke is an emerging indication, although ticagrelor’s use here is more selective and often limited by clinical guidelines and risk-benefit considerations. Other Cardiovascular Conditions like peripheral artery disease or high-risk stable angina contribute to a smaller but growing segment as research continues to explore expanded use cases.

By Distribution Channel

Hospital Pharmacies hold a dominant share due to the acute nature of cardiovascular events treated in hospital settings, especially immediately post-infarction or during procedures like angioplasty. Retail Pharmacies are important for continuing outpatient therapy, especially for long-term maintenance doses like the 60 mg formulation.

Online Pharmacies are gaining popularity due to convenience, rising digital health adoption, and the growth of e-prescriptions, particularly in urban areas and during the COVID-19 pandemic era.

By End User

Hospitals are the primary end users, especially for emergency care and initial diagnosis and treatment of ACS or myocardial infarction. They play a key role in initiating ticagrelor therapy. Cardiology Clinics serve as follow-up and maintenance centers, where long-term medication management decisions are made.

Ambulatory Surgical Centers may use ticagrelor as part of perioperative care in cardiovascular procedures, though their market share is smaller compared to hospitals. Homecare Settings are becoming more significant, particularly in developed countries, as more patients transition to managing chronic cardiovascular conditions at home with regular medication adherence and remote monitoring.

Regional Analysis

North America

North America, particularly the United States, holds a dominant share in the global ticagrelor market due to a high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and strong adoption of branded drugs like Brilinta.

The presence of major pharmaceutical players and favorable reimbursement policies further support market growth. The region also benefits from early access to new formulations, clinical trials, and robust physician awareness. However, rising healthcare costs are prompting a gradual shift toward generic alternatives.

Europe

Europe is the second-largest market, with countries like Germany, the UK, France, and Italy leading in usage. The region has a high burden of cardiac diseases and strong adherence to clinical guidelines that recommend ticagrelor for acute coronary syndrome and myocardial infarction.

The presence of universal healthcare systems ensures broad access, although cost-control measures in some countries encourage the use of generics. AstraZeneca’s strong regional presence and marketing efforts have supported Brilique’s uptake across major European markets.

Asia Pacific

The Asia Pacific region is experiencing the fastest growth in the ticagrelor market, driven by the rising incidence of heart disease, rapid urbanization, and improvements in healthcare access. Countries like China, India, Japan, and South Korea are seeing increased investment in healthcare infrastructure and growing awareness about preventive cardiology.

However, cost sensitivity and limited insurance coverage in some parts of the region hinder widespread adoption of branded drugs, creating strong opportunities for generic ticagrelor manufacturers.

Latin America

The ticagrelor market in Latin America is moderately growing, with Brazil, Mexico, and Argentina being the key contributors. The increasing burden of non-communicable diseases like hypertension and diabetes, which are major risk factors for cardiovascular conditions, is boosting demand.

However, economic constraints, uneven healthcare access, and limited awareness pose challenges. Growth is expected as more countries expand their public healthcare coverage and as generic versions become more widely available.

Middle East & Africa (MEA)

The MEA region represents a smaller but gradually expanding market. Countries like Saudi Arabia, the UAE, and South Africa are showing growing demand for advanced cardiovascular treatments, supported by rising healthcare investments and government-led health initiatives.

However, large parts of the region still face limited access to advanced therapies, low physician awareness, and budget constraints. Despite these challenges, the market holds potential due to increasing diagnosis rates and strategic entry of global pharmaceutical companies.

Recent Development

1. August 2024 AstraZeneca Initiated a Phase I clinical trial in Germany to explore new indications for ticagrelor, potentially expanding its therapeutic applications. 
2. March 2021 AstraZeneca Received approval from China’s National Medical Products Administration (NMPA) for Brilinta (ticagrelor) to prevent stroke in patients with acute ischemic stroke or transient ischemic attack (TIA). 
3. February 2021 Dr. Reddy’s Laboratories Launched a generic version of ticagrelor tablets in the United States following approval from the U.S. Food and Drug Administration (FDA), enhancing accessibility to antiplatelet therapy.
4. January 2021 Glenmark Pharmaceuticals Introduced its generic version of ticagrelor tablets in India under the brand name Ticonar, expanding its cardiovascular portfolio.
5. December 2020 Mylan N.V. Launched an authorized generic version of ticagrelor tablets in the United States, providing a cost-effective alternative for patients requiring antiplatelet therapy. 
6. September 2024 Apotex Inc. Became the first generic manufacturer to launch dasatinib tablets in the United States, demonstrating its capability in introducing generic versions of complex medications. 
7. February 2025 Apotex Inc. Acquired U.S. rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil), expanding its portfolio in the central nervous system therapeutic area.